Precigen (PGEN)
NASDAQ:PGEN
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.18Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum driven by full FDA approval and an accelerating launch: substantive payer coverage (≈215M lives, ~90% of insured lives), rapid growth in the patient hub (>300 patients), and an aggressive Q1 revenue expectation (> $18M) support a positive commercial inflection. These positives are balanced against large historical net losses ($429.6M in 2025), a significant SG&A increase (69.8%) tied to the launch, limited product revenue in 2025 due to a late-quarter start, and operational execution risks (conversion timing, EMA timeline, gross-to-net pressure). Overall, the highlights around product approval, payer uptake, and early demand materially outweigh the financial and operational challenges disclosed, leading to a constructive outlook for the company’s commercial transition.Company Guidance
Strong Early Commercial Ramp and Q1 Revenue Guidance
Net product revenue for Q4 2025 was $3.4 million (shipments began in November 2025). Management expects Q1 2026 product revenue to exceed $18.0 million (first full quarter of commercial sales), signaling a rapid ramp in uptake.
FDA Full Approval with Broad Label and Compelling Clinical Data
The therapy received full FDA approval for adult recurrent respiratory papillomatosis (RRP) with a broad label (no restriction based on number of prior surgeries). Management highlighted unmatched complete response rates and durable responses with >3 years follow-up; an expert consensus paper in a top specialty journal recommends the product as the preferred first-line immunotherapy.
Rapid Expansion of Payer Coverage and Patient Hub Growth
Payer coverage expanded from ~170 million lives in early January to ~215 million lives (management states ~90% of insured U.S. lives covered across commercial, Medicare and Medicaid). The company's patient support hub grew from over 200 patients in mid-January to well over 300 patients, indicating strong demand.
Broad Adoption Across Institution Types and Operational Enablers
Management reported accelerating utilization across academic centers, large institutions and community practices (including community uptake seen as a significant contributor). A permanent J-code is effective April 1 to streamline billing and prior authorization workflows; logistics solutions (cold-chain, just-in-time shipments) were put in place to support community practices.
Balance Sheet and Path to Cash-Flow Breakeven
Cash, cash equivalents and investments at year-end were $100.4 million. Management believes these funds plus anticipated product sales will fund operations through cash-flow breakeven, which they currently expect to occur in 2026.
Pipeline and International Development Plans
Plans to initiate a pediatric RRP trial in Q4 of the year were disclosed. The marketing authorization application to the EMA is under review (geographic expansion) and the PRGN-2009 program (AdenoVerse platform targeting HPV16/18) is in Phase 2 combination studies for HPV-associated cancers.
PGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 25, 2026 | $3.10 | $3.89 | +25.48% |
Nov 13, 2025 | $3.86 | $4.85 | +25.65% |
Aug 12, 2025 | $1.74 | $1.80 | +3.45% |
May 14, 2025 | $1.28 | $1.31 | +2.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Precigen (PGEN) report earnings?
Precigen (PGEN) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is Precigen (PGEN) earnings time?
Precigen (PGEN) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PGEN EPS forecast?
PGEN EPS forecast for the fiscal quarter 2026 (Q1) is -0.03.